Candida albicans peritonitis in a dog.
OBJECTIVE
To describe the clinical management of a case of Candida albicans peritonitis in a dog and discuss the pathogenicity of Candida peritonitis along with treatment using the fungistatic agent, fluconazole.


METHODS
A 15-week-old Papillon developed peritonitis secondary to enterectomy site dehiscence. A pure growth of Candida albicans was obtained from the abdominal fluid. Surgical repair of the dehiscence was performed and antifungal therapy instituted with fluconazole postoperatively. A marked exudative process was noted postoperatively with production of large volumes of fluid from the abdominal drain. Fresh frozen plasma and pentastarch were provided for oncotic support. Recovery was complicated by megaesophagus, however, the patient gradually improved and was discharged 11 days after surgery.


CONCLUSIONS
To our knowledge, this is the first case report of successful treatment of Candida albicans peritonitis in a dog. A marked exudative process was noted during therapy requiring significant oncotic support. Resolution of the disease process was achieved with surgical intervention and antifungal therapy.
Murdoch University Veterinary Hospital, Murdoch, WA 6150, Australia. ryan.ong@murdoch.edu.au
Ryan K C
RK
Ong
Anthea L
AL
Raisis
Katrin L
KL
Swindells
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy* / Q000382:microbiology; D004285:Dogs; D015725:Fluconazole / Q000627:therapeutic use*; D008297:Male; D010538:Peritonitis / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D013530:Surgical Wound Infection / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D016896:Treatment Outcome
D000935:Antifungal Agents; D015725:Fluconazole